A phase I and pharmacokinetic study of indisulam in combination with carboplatin

被引:0
作者
C Dittrich
A S Zandvliet
M Gneist
A D R Huitema
A A J King
J Wanders
机构
[1] Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna) and ACR–ITR VIEnna,Third Medical Department – Centre for Oncology and Haematology
[2] The Netherlands Cancer Institute/Slotervaart Hospital,Department of Pharmacy and Pharmacology
[3] Eisai Ltd.,undefined
来源
British Journal of Cancer | 2007年 / 96卷
关键词
indisulam; carboplatin; phase I; pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
Indisulam (E7070) is an anticancer agent that is currently being evaluated in phase II clinical studies. A significant reduction in glutathione synthetase and glutathione reductase transcripts by indisulam provided a molecular basis for its combination with platinum agents. Indisulam demonstrated high anti-tumour activity in various preclinical cancer models. The objectives of this study were (1) to determine the recommended dose of indisulam in combination with carboplatin in patients with solid tumours and (2) to evaluate the pharmacokinetics of the combination. Patients with solid tumours were treated with indisulam in combination with carboplatin. Indisulam (350, 500, or 600 mg m−2) was given as a 1-hour intravenous infusion on day 1 and carboplatin (5 or 6 mg min ml−1) as an intravenous infusion over 30 min on day 2 of a three-weekly cycle. Sixteen patients received study treatment and were eligible. Thrombocytopenia was the major dose limiting toxicity followed by neutropenia. Both drugs contributed to the myelosuppressive effect of the combination. Indisulam 500 mg m−2 in combination with carboplatin 6 mg min ml−1 was identified not to cause dose limiting toxicity, but a delay of re-treatment by 1 week was required regularly to allow recovery from myelosuppression. The recommended dose and schedule for an envisaged phase II study in patients with non-small cell lung cancer is indisulam 500 mg m−2 in combination with carboplatin 6 mg min ml−1 repeated four-weekly. Patients who do not experience severe thrombocytopenia at cycle 1 will be permitted to receive an escalated dose of indisulam of 600 mg m−2 from cycle 2 onwards.
引用
收藏
页码:559 / 566
页数:7
相关论文
共 215 条
  • [1] Abd-Allah AR(2005)-carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC) Arch Toxicol 79 406-413
  • [2] Al-Majed AA(1996)Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study Semin Oncol 23 19-21
  • [3] Al-Yahya AA(2004)Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1, 4-benzene disulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry Rapid Commun Mass Spectrom 18 2839-2848
  • [4] Fouda SI(1994)First Euro-American Forum on lung cancer treatment of the European School of Oncology Eur J Cancer 30A 710-713
  • [5] Al-Shabana OA(1982)Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II Cancer Chemother Pharmacol 9 140-147
  • [6] Belani CP(1989)Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1748-1756
  • [7] Aisner J(2000)Patterns of practice survey for non-small cell lung carcinoma in the US Cancer 88 1336-1346
  • [8] Hiponia D(1976)Prediction of creatinine clearance from serum creatinine Nephron 16 31-41
  • [9] Ramanathan R(2006)More on case 7–2006 N Engl J Med 355 1502-1503
  • [10] Beumer JH(2006)Flat dosing of carboplatin is justified in adult patients with normal renal function Clin Cancer Res 12 6502-6508